<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959124</url>
  </required_header>
  <id_info>
    <org_study_id>IRB106-68-A</org_study_id>
    <nct_id>NCT03959124</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation for Alzheimer's Disease</brief_title>
  <official_title>The Effect of Deep Brain Stimulation on Memory Network and Neurological Function of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Deep brain stimulation (DBS) is used to modulate the activity of dysfunctional
      brain circuits. The safety and preliminary efficacy of nucleus basalis of Meynert (NBM)-DBS
      in Alzheimer's disease (AD) is proved in a recent phase 1 clinical trial, yet, the mechanism
      still unknown.

      Objective: 1. To compare the brain structure and functional circuits between a) AD patients
      with optimal drug treatment (ODT) plus NBM-DBS, b) AD with ODT and c) normal age-and
      sex-matched control. 2. To evaluate the clinical effectiveness of NBM-DBS in AD patients
      60-75 year-old. 3. To evaluate the abnormal functional circuitry response to acute and
      chronic NBM-DBS in AD.

      Methods: A total of 30 subjects (10 subjects of AD with ODT plus NBM-DBS; 10 subjects of AD
      with ODT and 10 subjects of normal age-and sex-matched subjects) will be enrolled in this
      prospective, with normal control, Phase II study. Study tools will include clinical rating
      batteries, structure and functional imaging of magnetic resonance (MR) and positron emission
      tomography (PET), and electroencephalogram (EEG).

      Expected Results: NBM-DBS will be proved to be an safe and effective treatment modality in AD
      patients 60-75 year-old. Through multi-modal images and EEG analysis, the possible action
      mechanisms of NBM-DBS on memory circuit will be discussed. The study results may shed a light
      on this helpless neurodegenerative disease of dementia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)</measure>
    <time_frame>One year</time_frame>
    <description>Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale; Total scores range from 0-70. Higher scores (≥ 18) indicate worse cognitive function. It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia, Alzheimer Type</condition>
  <condition>Deep Brain Stimulation</condition>
  <arm_group>
    <arm_group_label>AD with DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer's disease subjects with optimal medication therapy and with DBS treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD without DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alzheimer's disease subjects with optimal medication therapy and without DBS treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Matched aged and demographics subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep brain stimulation</intervention_name>
    <description>Brain stimulation electrodes at parameters 2.0~4.5 V；60 μs；20 Hz</description>
    <arm_group_label>AD with DBS</arm_group_label>
    <other_name>Deep brain stimulation electrodes (Medtronic or Abbott)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best medical treatment for Alzheimer's disease</intervention_name>
    <description>Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment</description>
    <arm_group_label>AD with DBS</arm_group_label>
    <arm_group_label>AD without DBS</arm_group_label>
    <other_name>Exelon (Rivastigmine Tartrate), Witgen (Memantine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For groups (AD with/ without DBS)

          1. Confirmed Alzheimer's dementia diagnosis

          2. Regular medications taking for at least 3 months

          3. Clinical Dementia Rating: 0.5 - 2

          4. Mini Mental Status Examination: ≦ 26

          5. Amyloid PET: positive

          6. Informed consent signed by patients or families

        For normal control group

          1. No cognitive impairment (Mini Mental Status Examination)

          2. Amyloid PET: negative

          3. Informed consent signed by patients and families

        Exclusion Criteria:

        For groups (AD with/ without DBS)

          1. Structural lesions identified by Magnetic resonance imaging (ex: stroke, brain
             surgery)

          2. Other neurodegenerative/ neuropsychiatric diseases

          3. Systemic medical diseases with cognitive impairment (ex: anemia, thyroid disease)

          4. Can't have regular follow-up visit

        For normal control group

          1. Structural lesions identified by Magnetic resonance imaging (ex: stroke, brain
             surgery)

          2. Dementia/ neurodegenerative/ neuropsychiatric diseases

          3. Systemic medical diseases with cognitive impairment (ex: anemia, thyroid disease)

          4. Can't have regular follow-up visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin-Yuan Chen, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shin-Yuan Chen, MD.</last_name>
    <phone>+886-3-8561825</phone>
    <phone_ext>12151</phone_ext>
    <email>william.sychen@msa.hinet.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting-Wen Hou, BS.</last_name>
    <phone>+886-3-8561825</phone>
    <phone_ext>12151</phone_ext>
    <email>tcpdcenter@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien City</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Yuan Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shin Yuan Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Kuhn J, Hardenacke K, Lenartz D, Gruendler T, Ullsperger M, Bartsch C, Mai JK, Zilles K, Bauer A, Matusch A, Schulz RJ, Noreik M, Bührle CP, Maintz D, Woopen C, Häussermann P, Hellmich M, Klosterkötter J, Wiltfang J, Maarouf M, Freund HJ, Sturm V. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia. Mol Psychiatry. 2015 Mar;20(3):353-60. doi: 10.1038/mp.2014.32. Epub 2014 May 6.</citation>
    <PMID>24798585</PMID>
  </reference>
  <reference>
    <citation>Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T. Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2018 Feb 1;75(2):169-178. doi: 10.1001/jamaneurol.2017.3762.</citation>
    <PMID>29255885</PMID>
  </reference>
  <reference>
    <citation>Kumbhare D, Palys V, Toms J, Wickramasinghe CS, Amarasinghe K, Manic M, Hughes E, Holloway KL. Nucleus Basalis of Meynert Stimulation for Dementia: Theoretical and Technical Considerations. Front Neurosci. 2018 Sep 3;12:614. doi: 10.3389/fnins.2018.00614. eCollection 2018.</citation>
    <PMID>30233297</PMID>
  </reference>
  <reference>
    <citation>Kuhn J, Hardenacke K, Shubina E, Lenartz D, Visser-Vandewalle V, Zilles K, Sturm V, Freund HJ. Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia. Brain Stimul. 2015 Jul-Aug;8(4):838-9. doi: 10.1016/j.brs.2015.04.002. Epub 2015 Apr 18.</citation>
    <PMID>25991080</PMID>
  </reference>
  <reference>
    <citation>Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature. 2016 Nov 10;539(7628):187-196. doi: 10.1038/nature20412. Review.</citation>
    <PMID>27830780</PMID>
  </reference>
  <reference>
    <citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(7632):230-235. doi: 10.1038/nature20587. Erratum in: Nature. 2018 Oct;562(7725):E1.</citation>
    <PMID>27929004</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance image</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

